|
gptkbp:instanceOf
|
gptkb:drug
gptkb:organic_arsenical_compound
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:ATCCode
|
P01CD01
|
|
gptkbp:CASNumber
|
494-79-1
|
|
gptkbp:chemicalFormula
|
C12H15AsN6OS2
|
|
gptkbp:contraindication
|
hypersensitivity to arsenic compounds
|
|
gptkbp:developedBy
|
gptkb:Aventis
|
|
gptkbp:discoveredIn
|
1949
|
|
gptkbp:isA
|
gptkb:antineoplastic_agent
arsenic-containing drug
|
|
gptkbp:KEGGID
|
D02368
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MeSH_ID
|
D008557
|
|
gptkbp:molecularWeight
|
398.34 g/mol
|
|
gptkbp:origin
|
synthesized from dimercaprol and melarsen oxide
|
|
gptkbp:otherName
|
gptkb:Mel_B
arsobal
|
|
gptkbp:PubChem_CID
|
4057
6706
|
|
gptkbp:riskFactor
|
high toxicity
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:encephalopathy
fever
vomiting
hypertension
rash
polyneuropathy
|
|
gptkbp:UNII
|
8U6A1WP42K
|
|
gptkbp:usedFor
|
treatment of African trypanosomiasis
treatment of sleeping sickness
|
|
gptkbp:usedIn
|
late-stage Trypanosoma brucei infection
|
|
gptkbp:bfsParent
|
gptkb:Trypanosomiasis
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
melarsoprol
|